L'Association des Entreprises Psychédéliques
L'Association des Entreprises Psychédéliques
Press Release — sept. 21, 2022
TORONTO, ON (Canada Newswire) – September 21st, 2022 – Research into Psychedelics shows promising advantages to existing therapies and Canada needs to make room for healthcare innovation, according to Psychedelics Canada: the not-for-profit trade association representing Canadian psychedelic medicine and therapy companies.
“Canada has an emerging psychedelics industry with the potential to improve the mental and physical health of millions worldwide—led by the members of our industry association,” said Nick Kadysh, Board Chair of Psychedelics Canada. “But we need federal policy makers to make regulatory reform a priority, otherwise we risk ceding leadership to competitive countries.”
“Despite some progress, Canada risks falling behind in offering these lifechanging therapies to the people who need them,” said Liam Bedard, Coordinator of Psychedelics Canada. “Canada needs to make medicinal psychedelics a public health priority – by funding research, enabling clinical trials, but most importantly by reducing the regulatory burden which slows down scientific progress.”
PsyCan members will be speaking to policymakers at the federal and provincial levels in the coming months about easing requirements for patient access to treatments involving psychedelic molecules, improving regulatory timelines pertaining to controlled substances licenses, launching clinical research to continue to prove the merits of psychedelic-assisted therapies, and continuing to develop a secure supply chain for psychedelic molecules for scientific purposes.
PsyCan has also launched an online awareness campaign to encourage policymakers to make regulatory reform for psychedelic medicine a priority. Learn more at: psychedelicscanada.org/advocacy.
“We believe in a future where psychedelic therapies, administered by qualified health care practitioners, are among the available treatment options for patients who may benefit,” said Bedard. “Only by embracing innovation in mental health treatment can we improve the lives of Canadians.”
For more information, please contact:
Liam Bedard
Coordinator
Psychedelic Businesses Association, operating as Psychedelics Canada
Email: admin@psychedelicscanada.org
Phone: 011 32 468 37 85 90
Psychedelics Canada, incorporated as the Psychedelics Businesses Association, is the not-for-profit trade association for the legal psychedelics industry. Psychedelics Canada is dedicated to working collaboratively to advancing government regulation, scientific research, and the specific needs of the legal psychedelics industry. Member companies of Psychedelics Canada are devoted to collective action, and motivated by a belief in the promise of Psychedelic molecules as therapeutic treatments. Member companies represent research, development, manufacturing, and clinic operations. At the time of incorporation, Psychedelics Canada was the first national-level trade association for the legal psychedelics industry anywhere in the world.
-30-
À PROPOS DE PSYCHÉDÉLIQUES CANADA
Psychédéliques Canada, connue aussi comme étant l’Association de l’industrie des psychédéliques, est une association professionnelle à but non lucratif qui représente l’industrie légale des hallucinogènes. Elle mise sur la collaboration pour faire progresser la réglementation gouvernementale, avancer la recherche scientifique et satisfaire les besoins de l’industrie dans son ensemble. Les entreprises membres de Psychédéliques Canada croient fermement au pouvoir de la mobilisation collective ainsi qu’aux vertus thérapeutiques des molécules psychédéliques. Ces entreprises sont actives dans différents secteurs : recherche et développement, fabrication, activités cliniques. Lorsque Psychédéliques Canada a été officiellement constituée, il n’existait aucune autre association professionnelle nationale dans le monde se faisant la voix de l’industrie légale des hallucinogènes.
Liam Bedard, Coordonnateur
media@psychedelicscanada.org